PDF 
Views 
Share
Prevalence and Susceptibility of Carbapenem Resistance Gram-Negative Bacteria in an ICU Setup
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(S 01): S1-S19
DOI: DOI: 10.1055/s-0042-1755512
Correspondence to: saritaotta@gmail.com
Background: With the increasing use of carbapenems in clinical practice has led to emergence of carbapenem-resistant Gram-negative bacilli which now poses a great threat to human health. Carbapenem resistant Gram-negative bacilli are priority pathogens with limited options available for their treatment.
Materials and Methods: This is a prospective study over a period of 5 months during which, of the samples received from ICU, 59 samples grew Gram-negative bacilli for which identification and susceptibility was performed by Vitek-2 method. Carbapenem resistant Gram-negative bacilli (CRGNB) were considered in the study. Intrinsic carbapenem resistant bacilli, non-ICU samples were excluded from the study.
Results: Of the 60 carbapenem resistant isolates, 23.7%-belonged to 41 to 50 years of age group followed closely by 51 to 60 (22.03%) and 61 to 70 (18.6%) years of age groups; males outnumbering the females. Most of the isolates were cultured from Respiratory samples (sputum, tracheal aspirate, and BAL). Klebsiella pneumoniae constituted the highest proportion (36.7%) of CRGNB followed by Acinetobacter spp. (22%). Tigecycline, colistin, and aminoglycosides were the most useful antibiotics for CRGNB. Klebsiella spp. had the highest resistance (75%) to tigecycline while Acinetobacter spp. had the highest resistance to colistin.
Conclusion: CRGNB is on the rise in ICU set-up, Klebsiella spp. dominating the scenario. The available options for these bacilli are limited to tigecycline, colistin, and aminoglycosides. Tigecycline is the most effective antibiotic for E. coli and Acinetobacter spp. but colistin should be preferred for Klebsiella spp.
Publication History
Article published online:
22 August 2022
© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Correspondence to: saritaotta@gmail.com
Background: With the increasing use of carbapenems in clinical practice has led to emergence of carbapenem-resistant Gram-negative bacilli which now poses a great threat to human health. Carbapenem resistant Gram-negative bacilli are priority pathogens with limited options available for their treatment.
Materials and Methods: This is a prospective study over a period of 5 months during which, of the samples received from ICU, 59 samples grew Gram-negative bacilli for which identification and susceptibility was performed by Vitek-2 method. Carbapenem resistant Gram-negative bacilli (CRGNB) were considered in the study. Intrinsic carbapenem resistant bacilli, non-ICU samples were excluded from the study.
Results: Of the 60 carbapenem resistant isolates, 23.7%-belonged to 41 to 50 years of age group followed closely by 51 to 60 (22.03%) and 61 to 70 (18.6%) years of age groups; males outnumbering the females. Most of the isolates were cultured from Respiratory samples (sputum, tracheal aspirate, and BAL). Klebsiella pneumoniae constituted the highest proportion (36.7%) of CRGNB followed by Acinetobacter spp. (22%). Tigecycline, colistin, and aminoglycosides were the most useful antibiotics for CRGNB. Klebsiella spp. had the highest resistance (75%) to tigecycline while Acinetobacter spp. had the highest resistance to colistin.
Conclusion: CRGNB is on the rise in ICU set-up, Klebsiella spp. dominating the scenario. The available options for these bacilli are limited to tigecycline, colistin, and aminoglycosides. Tigecycline is the most effective antibiotic for E. coli and Acinetobacter spp. but colistin should be preferred for Klebsiella spp.
No conflict of interest has been declared by the author(s).
Publication History
Article published online:
22 August 2022
© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India